NYSE$TFX
Teleflex Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Teleflex reported solid fourth quarter and full year results driven by strong execution and a diversified product portfolio.
Teleflex Incorporated announced its Q4 2021 financial results, with reported revenues of $761.9 million, a 7.1% year-over-year increase, and adjusted diluted EPS of $3.60, up 10.8% year-over-year. The company provided 2022 guidance, including GAAP revenue growth expected to be 2.3% to 3.8% and adjusted diluted EPS from continuing operations of $13.70 to $14.30.
- Reported revenues increased by 7.1% year-over-year to $761.9 million.
- Constant currency revenue growth was 7.9%.
- GAAP diluted EPS from continuing operations was $2.69, compared to $1.62 in the prior year period.
- Adjusted diluted EPS from continuing operations increased by 10.8% year-over-year to $3.60.
Headline financials
Revenue & EPS history
Teleflex · Revenue · Quarterly
$762M
Revenue by segment
Teleflex · $452M total across 1 segment · Q4 2021
- Americas Segment$452M+7.7%100.0%
Forward guidance
Teleflex provided its outlook for full year 2022, expecting GAAP revenue growth of 2.3% to 3.8% and adjusted diluted earnings per share of $13.70 to $14.30.
Tailwinds
- GAAP revenue growth expected to be 2.3% to 3.8%.
- Constant currency revenue growth of 4.0% to 5.5% inclusive of a 1.6% headwind from the initial phase of the respiratory divestiture completed on June 28, 2021.
- GAAP diluted EPS from continuing operations of $8.90 to $9.50.
- Adjusted diluted EPS from continuing operations guidance range of $13.70 to $14.30 inclusive of an estimated $0.17 headwind from the respiratory divestiture.
- The company believes Teleflex remains well-positioned to drive durable growth and manage the challenges of the current environment.
Headwinds
- GAAP revenue growth reflects an estimate of an approximately 1.7% negative impact of foreign exchange rate fluctuations.
- Constant currency revenue growth includes an approximately 1.6% year-over-year headwind from the initial phase of the respiratory divestiture completed on June 28, 2021.
- The divestiture of the respiratory assets is estimated to be dilutive to 2022 adjusted earnings per share by $0.17.
- Adverse economic conditions associated with the COVID-19 global health pandemic.
- Potential changes in business relationships with major customers or suppliers.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
-0.4%
Avg return
Earnings day
-2.6%
Avg return
5 days after
-1.9%
Avg return
30 days after
53%
36 / 68 earnings
Positive
+12.5%
Q3 2023
Best reaction
-21.7%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +6.9% | +4.6% | +5.2% | |
| Q4 2025 | +6.5% | +9.2% | +3.9% | |
| Q3 2025 | -13.3% | -10.0% | -3.4% | |
| Q1 2025 | -8.2% | -12.0% | -10.8% | |
| Q4 2024 | -21.7% | -26.4% | -22.4% | |
| Q3 2024 | -10.2% | -13.5% | -18.0% | |
| Q2 2024 | +7.3% | +4.5% | +11.0% | |
| Q1 2024 | -4.0% | -4.7% | -1.2% | |
| Q4 2023 | -5.3% | -9.9% | -12.0% | |
| Q3 2023 | +12.5% | +9.2% | +21.4% | |
| Q2 2023 | -4.3% | -7.6% | -14.1% | |
| Q1 2023 | -5.2% | -7.4% | -13.1% | |
| Q4 2022 | -2.3% | -1.0% | +3.4% | |
| Q3 2022 | +3.1% | +5.6% | +8.6% | |
| Q2 2022 | -9.8% | -5.9% | -15.9% | |
| Q1 2022 | -9.7% | -9.9% | -8.3% | |
| Q4 2021 | +6.4% | +3.4% | +5.3% | |
| Q3 2021 | -2.5% | +0.9% | -16.7% | |
| Q2 2021 | -0.5% | -3.6% | -2.8% | |
| Q1 2021 | -4.8% | -7.0% | -9.4% | |
| Q4 2020 | -0.6% | +0.8% | +3.2% | |
| Q3 2020 | -5.0% | -0.8% | +10.8% | |
| Q2 2020 | -7.0% | -8.2% | -4.0% | |
| Q1 2020 | -6.7% | -3.5% | +2.8% | |
| Q4 2019 | -6.3% | -11.9% | -38.3% | |
| Q3 2019 | +4.9% | +1.9% | +7.1% | |
| Q2 2019 | +6.4% | +6.8% | +7.1% | |
| Q1 2019 | +7.0% | +4.9% | +2.7% | |
| Q4 2018 | -0.4% | +0.7% | +5.3% | |
| Q3 2018 | +6.4% | +6.9% | +14.4% | |
| Q2 2018 | -9.2% | -12.4% | -8.6% | |
| Q1 2018 | +0.6% | -0.7% | -0.2% | |
| Q4 2017 | -5.5% | -6.0% | -6.3% | |
| Q3 2017 | +6.1% | +7.7% | +9.9% | |
| Q2 2017 | +5.5% | +4.9% | +3.7% | |
| Q1 2017 | -4.4% | -7.2% | -1.2% | |
| Q4 2016 | +3.1% | +3.9% | +5.9% | |
| Q3 2016 | -9.7% | -11.2% | -2.7% | |
| Q2 2016 | +3.2% | +3.0% | +4.4% | |
| Q1 2016 | -2.8% | — | — | |
| Q4 2015 | +9.6% | — | — | |
| Q3 2015 | +2.4% | — | — | |
| Q2 2015 | -4.5% | — | — | |
| Q1 2015 | +0.6% | — | — | |
| Q4 2014 | +4.6% | — | — | |
| Q3 2014 | +0.7% | — | — | |
| Q2 2014 | +1.9% | — | — | |
| Q1 2014 | +1.6% | — | — | |
| Q4 2013 | +3.0% | — | — | |
| Q3 2013 | +5.5% | — | — | |
| Q2 2013 | +0.2% | — | — | |
| Q1 2013 | -5.9% | — | — | |
| Q4 2010 | -0.4% | — | — | |
| Q4 2012 | +1.0% | — | — | |
| Q3 2012 | +3.7% | — | — | |
| Q2 2012 | +4.4% | — | — | |
| Q1 2012 | +0.9% | — | — | |
| Q4 2011 | +0.9% | — | — | |
| Q3 2011 | -1.2% | — | — | |
| Q2 2011 | +0.9% | — | — | |
| Q1 2010 | +2.9% | — | — | |
| Q1 2011 | +0.7% | — | — | |
| Q4 2008 | -2.6% | — | — | |
| Q3 2009 | -3.4% | — | — | |
| Q3 2010 | -3.4% | — | — | |
| Q2 2009 | +7.3% | — | — | |
| Q4 2009 | +7.3% | — | — | |
| Q2 2010 | +7.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro